2022 Fiscal Year Final Research Report
The mechanism of ROS-mediated synovitis and flare in rheumatoid arthritis
Project/Area Number |
20K09469
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 56020:Orthopedics-related
|
Research Institution | Toho University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
赤津 頼一 東邦大学, 医学部, 講師 (20795190)
中川 晃一 東邦大学, 医学部, 教授 (30400823)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 関節リウマチ / 寛解予測 / バイオマーカー / 酸化ストレス |
Outline of Final Research Achievements |
In this study, we aimed to investigate whether ROMs would be predictive of the clinical disease activity index (CDAI) remission, simplified disease activity index (SDAI) remission, or Boolean remission. Fifty-one biologic agents (BA)-naive RA patients were included in this observational study. Associations between ROMs, C-reactive protein, matrix metalloproteinase-3, DAS28-erythrocyte sedimentation rate (ESR), CDAI, SDAI, and health assessment questionnaire (HAQ) at 12 weeks and the DAS28, CDAI, SDAI, and Boolean remission rates at 52 weeks were investigated. The DAS28, CDAI, SDAI, and Boolean remission rates at 52 weeks were 66.7, 52.9, 54.9, and 54.9%, respectively. A multivariate logistic regression analysis revealed that ROMs and HAQ at 12 weeks were associated with the CDAI, SDAI, and Boolean remission at 52 weeks. Receiver operating characteristic analyses demonstrated that the cut-off value for CDAI, SDAI, and Boolean remission was 389.5 U.Carr.
|
Free Research Field |
関節リウマチ
|
Academic Significance and Societal Importance of the Research Achievements |
本研究の結果から、生物学的製剤治療開始後12週の血中ROM値が52週後のCDAI, SDAI, Boolean寛解予測のバイオマーカーとなる可能性が示唆された。本研究の強みは、血中ROMがCRP, MMP-3などの既存のバイオマーカーよりもCDAI, SDAI, Boolean基準の寛解予測に優れている点を示せた点である。ROC解析では高い感度を示せなかったが、血中ROMをコントロールすることによってCDAI, SDAI, Booleanなどのより厳しい寛解基準を達成することが可能になると考えられる。血中ROM値の測定が、RA患者の寛解予測に有用なバイオマーカーとして臨床への応用が期待される。
|